@article{article_549666, title={Are the conventional risk factors still valid for acute myeloid leukemia patients?}, journal={Konuralp Medical Journal}, volume={12}, pages={5–11}, year={2020}, DOI={10.18521/ktd.549666}, author={Yıldız, Abdulkerim and Maral, Senem and Albayrak, Murat and Pala, Çiğdem and Cömert, Pınar and Afacan Öztürk, Hacer Berna and Şahin, Osman}, keywords={leukemia,survival,age}, abstract={<p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">Objective: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">The
aim of this study was to investigate the survival data of patients with acute
myeloid leukemia (AML) and to determine the risk factors that can be easily evaluated. <b> </b> </span> </p> <p> <b> </b> </p> <b> </b> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">Method: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">A
retrospective analysis  was made of the <b> </b>AML patients admitted to our center between
2009-2018. Demographic data and disease data were analyzed and response rates,
overall survival (OS) and progression-free survival (PFS) rates were
calculated. Factors affecting survival were determined using Cox-regression
analysis. </span> </p> <p> <b> </b> </p> <b> </b> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">Results: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">A
total of 119 patients were included in the study during the 9-year study
period. Of these, 21 patients had secondary AML and 11 had acute promyelocytic
leukemia (APL). The mean follow-up period was 12.43 ± 15.63 months. OS of all
patients was 9.20 months and PFS was 7.23 months. Age and leukocyte count at
the time of diagnosis were found to have a significant impact on both OS and
PFS (p <0.05). <b> </b> </span> </p> <p> <b> </b> </p> <b> </b> <p class="MsoNormal" style="text-align:justify;line-height:150%;"> <b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">Conclusion: </span> </b> <span style="font-size:12pt;line-height:150%;font-family:’Times New Roman’, serif;">
In addition to genetic and molecular features, which are expensive and not
easily available, the age and leukocyte count of AML patients remain important as
prognostic factors. <b> </b> </span> </p> <p> <b> </b> </p> <b> </b>}, number={1}, publisher={Duzce University}